Jpn J Clin Oncol. 1985 Sep;15(3):559-62.
A Phase II study of co-administration of uracil and tegafur (UFT) was performed in 32 patients with unresectable hepatocellular carcinoma. A dose of 400 mg/m2/day of UFT was administered orally, three times a day, for more than 4 weeks. Of 26 patients evaluable for response, one (3.8%) showed a partial response of 9 months' duration. There were no complete responders. A dose-limiting toxicity was gastrointestinal tract disturbance. Six patients (18.8%) had to discontinue UFT treatment because of gastrointestinal toxicity. The clinical advantage of tegafur in the treatment of hepatocellular carcinoma was not enhanced by co-administration of uracil.
对32例无法切除的肝细胞癌患者进行了尿嘧啶与替加氟联合用药（UFT）的II期研究。UFT剂量为400mg/m²/天，口服，每日3次，持续4周以上。在26例可评估疗效的患者中，1例（3.8%）出现了持续9个月的部分缓解。无完全缓解者。剂量限制性毒性为胃肠道紊乱。6例患者（18.8%）因胃肠道毒性不得不停止UFT治疗。尿嘧啶与替加氟联合用药并未增强替加氟治疗肝细胞癌的临床优势。
